good everyone. you, Anne, morning, and Thank Mary
on have commercial teams the PYLARIFY been launch. update Our productive the during an start I'll third with quarter.
As mentioned, U.S. active the the with Anne two population. quarter Mary began X% we approximately third PMS, of covering
PMF Los Angeles, the Over major Houston quarter, such and New San course activated of Chicago, markets York, Diego, Washington, XX we as D.C. the additional covering
into to markets, PMF brings Florida this City. This two regions. those and additional Moreover, activated Northern and flying past doses in patients more key their California us of workflow we into activations selectively are to to institutions and week, Just advance as cancer PMS, in Kansas Dallas the activation. in we such advance added PYLARIFY markets access prostate which allows local of PYLARIFY PMF of cancer prostate and enables incorporate XX
have cancer. to been centers facilities prostate hospitals and of towards comprising government perspective, base, date, We we our the we customer continue with XX% the imaging to of of contracted demand academic and XXXX. PMF of availability have broad of ordering a by across treat geographic independent our expansion who orders From goal first happy targeted two-thirds in U.S. the approximately stated the with previously with ongoing U.S. our across year-end in Together institutions with XX% breadth work our half approximately partners, XX%.
the setting, We the have which with to outpatient pleased particularly adoption payment is by even been much prior hospital in initiation. of hospitals, pass-through
rate of with are date. encouraged to the We ordered having by XX% over of doses multiple demand, also repeat customers
relevance Medicine clinical PSMA Molecular cancer. Comprehensive very used intermediate, Society PET prostate recognized appropriate The of and prostate the recurrent for management by With Importantly, are as well oncology piflufolastat XX NCCN, disease policy XX The cancer the their now recently high National payers. guidelines as or updated standard unfavorable imaging in in of SNMMI, the for potential the choosing in PET included imaging added F in of imaging, use clinical guidelines guidelines. PSMA-targeted areas quarter, developed medical also have this plan payer international impact to Nuclear the of criteria prostate Association, the for were included with associations. NCCN widely as cancer during Imaging, Cancer and Nuclear the or a and American F high-risk Network, key piflufolastat We clinicians men including PSMA and with and facilitate in cancer. American diagnostic communities Medicine, other in believe prostate patients guidelines. as and PSMAs this College of treatment treatment of American Urological awareness options from PYLARIFY of and for physicians agent and input raises Physicians further the can overall for it diagnosing College the novel of Oncology, adoption the commercial Society will Clinical the These American
our goal submitted aligns during we for application we with Regarding payment, January X, Medicaid the Services, quarter, into to third the and pass-through across to or Centers go the to well coverage, payment our which the market stated pass-through XXXX. XXXX, CMS, broad access, specifically of of have availability PYLARIFY by end coding and Medicare effect and U.S. expect
notification HCPCS During enables effective our received code, as January will the X, that billing XXXX. be quarter, which of we also streamlined
We published are claims, paid of Contractors, have making Medicare The will Administrative either they progress in or of both PYLARIFY our indications. approved indicated majority guidance usage in indications. or coverage cover MACs, have
have work during and to commercial and policies XXXX. both continue formal have prior paid Advantage updated claims seen Finally, authorizations and to we Medicare we approved payers by with insurers,
in we build-out believe our dedicated We our which industry force, completed as team. the recently well access the also largest PSMA of is as the PET market sales
We needs coverage of and payment. activation, on-boarding the the work U.S. and prostate to to Switching PMF appropriate and community cancer now DEFINITY. meet contracting through coding to continue customer
double-digit in saw year-over-year growth quarter third sales. The
did quarter, the observe we utilization we traditional of to resurgence an of to pattern the During attribute echo COVID-XX. impact the that
quarter in quarter, noted nursing related We DEFINITY. echocardiograms, with in-person with to appropriate headwinds, of of specific were suboptimal strong staffing concern growth these Despite to deliver regional use drive above for XX% pleased with the medical variability, promotion to late and within the the albeit third reference and also continued remained hospitals awareness able our quarter. for DEFINITY the overall nationwide we in being of to team another staff
And return our Now sales portfolio. to studies, pre-COVID this business. again which business. overall from benefited on have continue TechneLite opportunistic negatively yet stable a SPECT ANSTO. Xenon to quarter, to continued Ventilation be contributor to impact our to we to levels, impact to our
Now I'll Anne. Mary back the call turn to
